Overview
- Moderna and Merck reported that the Phase 3 trial of intismeran plus KEYTRUDA met its recurrence‑free and distant metastasis‑free survival endpoints, giving the program a clearer path toward regulatory filings.
- Investors rapidly repriced Moderna after the readout, producing a multi‑hundred percent gain over the past year and prompting analyst upgrades, with some profit‑taking and intraday pullbacks following the rally.
- Wolfe Research raised its view of Moderna and estimated about $9.2 billion in unadjusted peak sales for intismeran across key indications, a projection that underpins bullish valuations but depends on full disclosed data.
- Company fundamentals remain a constraint: trailing revenue is small versus market value, operating losses are large, cash was $6.9 billion at quarter end, and management guidance implies cash will fall through 2026.
- Practical hurdles persist for commercial rollout because intismeran is individualized, requires tumor sequencing and bespoke manufacturing, Merck is covering roughly half development costs, and mixed pipeline results such as a norovirus interim miss add execution risk.